Compare MEI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | NGNE |
|---|---|---|
| Founded | 1946 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.3M | 327.8M |
| IPO Year | N/A | N/A |
| Metric | MEI | NGNE |
|---|---|---|
| Price | $6.90 | $19.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.50 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 329.8K | 199.7K |
| Earning Date | 12-03-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $984,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.08 | $6.88 |
| 52 Week High | $13.31 | $37.27 |
| Indicator | MEI | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 43.21 |
| Support Level | $6.77 | $19.03 |
| Resistance Level | $7.04 | $21.32 |
| Average True Range (ATR) | 0.28 | 1.34 |
| MACD | -0.04 | 0.26 |
| Stochastic Oscillator | 24.11 | 34.32 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.